Osteopontin Shapes Immunosuppression in the Metastatic Niche

Sabina Sangaletti1, Claudio Tripodo2, Sara Sandri1, Iliaria Torselli1, Caterina Vitali1, Chiara Ratti1, Laura Botti1, Alessia Burocchi1, Rossana Porcasi2, Andrea Tomirotti1, Mario P. Colombo1, and Claudia Chiodoni1

Abstract

The matricellular protein osteopontin (OPN, Spp-1) is widely associated with cancer aggressiveness when produced by tumor cells, but its impact is uncertain when produced by leukocytes in the context of the tumor stroma. In a broad study using Spp1−/− mice along with gene silencing in tumor cells, we obtained evidence of distinct and common activities of OPN when produced by tumor or host cells in a spontaneously metastatic model of breast cancer. Different cellular localization of OPN is associated with its distinct activities, being mainly secreted in tumor cells while intracellular in myeloid cells. OPN produced by tumor cells supported their survival in the blood stream, whereas both tumor- and host-derived OPN, particularly from myeloid cells, rendered the metastatic site more immunosuppressive. Myeloid-derived suppressor cells (MDSC) expanded with tumor progression at both primary and lung metastatic sites. Of the expanded monocytic and granulocytic cell populations of MDSCs, the monocytic subset was the predominant source of OPN. In Spp1−/− mice, the inhibition of lung metastases correlated with the expansion of granulocyte-oriented MDSCs. Notably, monocytic MDSCs in Spp1−/− mice were less suppressive than their wild-type counterparts due to lower expression of arginase-1, IL6, and phospho-Stat3. Moreover, fewer regulatory T cells accumulated at the metastatic site in Spp1−/− mice. Our data find correlation with lung metastases of human mammary carcinomas that are associated with myeloid cells expressing OPN. Overall, our results unveiled novel functions for OPN in shaping local immunosuppression in the lung metastatic niche. Cancer Res; 74(17); 4706-19. ©2014 AACR.

Introduction

Despite the advances in tumor prevention, early diagnosis, and therapeutic treatments, breast cancer remains one of the leading causes of death among women, mostly because of its predisposition to metastasize to distant sites, such as lungs, liver, brain, and bones. Much effort has been dedicated to the identification of molecular mechanisms conferring metastatic advantage to specific neoplastic clones so as to target the relevant pathways. Most of these pathways are also necessary for the local invasiveness of the primary tumor, and therefore their targeting may represent an appealing approach to contrast both aspects at the same time.

Besides genetically altered cancer cells, a tumor mass comprises a variety of normal cells that actively participate in tumor progression, including the metastatic process. Tumor and stromal cells produce the extracellular matrix (ECM), composed of structural proteins, such as collagens and fibronectin, and proteins that regulate cell function and their interaction, such as osteopontin (OPN, Spp-1), thrombospondin, SPARC (secreted protein acidic and rich in cysteine), and others, collectively referred to as matricellular proteins. These molecules are generally highly expressed during development, poorly in steady-state condition of adult tissues, whereas readily upregulated in wound healing and tissue remodeling. Matricellular proteins modulate several cellular processes, such as cell adhesion and migration, ECM deposition, cell survival, and proliferation (1). All these processes are also required for primary tumor growth and metastasis, in which matricellular proteins are often aberrantly expressed.

Among matricellular proteins, elevated OPN expression has been correlated with poor survival of patients with cancer with different tumor histotypes (2–4). Accordingly, clinical studies have shown high OPN plasma concentration in patients with metastatic tumors compared with normal samples, especially in breast cancer (5, 6). OPN protumoral and prometastatic activities have been demonstrated in mice and humans (1, 7, 8).
through the modulation of tumor cell migration, adhesion, and invasion (9–12).

Nevertheless, the comprehension of molecular mechanisms behind OPN functions in cancer remains far from complete (13). Most studies were centered on OPN produced by tumor cells, whereas only few have focused on OPN produced by the host (14–16), moreover without considering the metastatic setting.

This study, designed to dissect the role of OPN produced by either the tumor or the host in the context of breast cancer, provided the first evidence of OPN tuning the immunosuppressive microenvironment of the metastatic niche.

Materials and Methods

Cell line and mice

The 4T1 cell line (CRL-2539; LGC-Promochem) was derived from a murine spontaneous mammary carcinoma arising in a BALB/cICR mouse (17). BJMC3879 is a mammary adenocarcinoma developed in a BALB/c female upon inoculation into the inguinal mammary glands of mouse mammary tumor virus (MMTV; refs. 18, 19) and was kindly provided by Dr. Shibata (Osaka Medical College, Osaka, Japan). Female BALB/c mice, 8-week-olds, were purchased from Charles River Laboratories.

OPN gene silencing

Stable OPN gene silencing was obtained with the BLOCK-iT Pol II miR RNAi Expression Vector Kit from Invitrogen (see Supplementary Data for details and silencing sequences); Western blot analysis and ELISA on cell supernatants confirmed protein downmodulation (see Supplementary Data), whereas immunohistochemistry was performed on paraffin-embedded sections of primary tumor samples to confirm in vivo downmodulation.

In vitro migration, soft-agar colonization, anoikis, and adhesion assays

The motility of the 4T1 parental and silenced cells was evaluated in Transwell chambers as previously described (for more details, see Supplementary Data; ref. 20).

Anchorage-independent growth was determined in 0.3% agarose (SeaPlaque; FMC BioProducts) with a 0.6% agarose underlay. Cells (3 × 10⁵) were plated in semisolid medium (DMEM 10% FBS plus agar 0.3%) and incubated at 37°C in a humidified 5% CO₂ atmosphere. Colonies were counted under a microscope, blindly by two operators, after 8 to 12 days.

For an in vitro anoikis assay, 5 × 10⁵ cells were plated into 6-well tissue-treated plates previously coated or not with polyhydroxyethylmethacrylate (poly-HEMA; Sigma-Aldrich), in DMEM supplemented with 10% FBS or 2% FBS. After 20-hour incubation at 37°C, cells were collected, and anoikis was assessed counting viable cells/dead cells ratio by Trypan blue staining, blindly by two operators.

An adhesion assay was performed in 6-well plates in which 1G11 endothelial cells (a kind gift of Dr. Vecchi, Humanitas, Milan, Italy) were previously seeded 48 hours before (24 + 24 hours in the presence or absence of TNF, at 5 ng/mL to induce cell activation). 4T1GFP and 4T1silOPN GFP cells (5 × 10⁵) were added and let to adhere for 30 minutes; after PBS lx wash, cells were collected by trypsinization and GFP⁺ cells were evaluated by flow cytometry.

In vivo experiments

Parental, silenced, or control cell lines were inoculated orthotopically in the mammary fat pad (i.f.p.) at a dose of 5 × 10⁶ cells per mouse or intravenously (i.v.) at a dose of 10⁷ cells per mouse. For BJMC3879, 5 × 10⁶ cells per mouse were used. Primary tumor growth was measured once a week with a caliper, and the volume was calculated using the formula

\[ d^2 \times D/2 \]

where \( d \) and \( D \) are the short and long diameters, respectively.

For micrometastasis evaluation, lungs were removed from each mouse 28 days after tumor injection, and a clonogenic assay was performed (see Supplementary Data). For macro-metastasis evaluation, lungs were removed after intra-pleural perfusion with 15% China ink and fixed with Fekete solution (10% formaldehyde; 5% acetic acid in Et-OH 70%). Metastases, identified as white spots, were counted blindly by two operators. Alternatively, metastases were counted on H&E (hematoxylin and eosin)-stained lung sections under the microscope.

For a lung colonization assay, 4T1 cells or 4T1 silOPN527, both expressing GFP, were injected i.v. (2 × 10⁶ cells/mouse) in BALB/c mice. Peripheral blood leukocytes (PBL) were drawn at 2, 4, 8, 16, 24, and 48 hours and analyzed by flow cytometry for the presence of GFP⁺ CD45⁺ cells. For lung evaulation, 1, 3, 4, and 5 days after cells injection, mice were sacrificed, their lungs minced, digested with collagenase/hyaluronidase solution (STEMCELL Technologies), and analyzed by flow cytometry.

Histopathologic and immunohistochemical analysis

Samples, fixed in 10% neutral buffered formalin, were embedded in paraffin. Serial sections were cut at 4 μm from each block and stained with H&E. For immunohistochemical staining, the sections were dewaxed and rehydrated. After heat-mediated antigenic retrieval using a pH 9.0 Tris-EDTA buffer for 30 minutes in thermostatic water bath, the sections were incubated with 3% hydrogen peroxide for 5 minutes to quench endogenous peroxidase activity, and for 10 minutes with protein block (Novocastra, Ltd.). The sections were subsequently incubated with primary antibodies: anti-human/mouse OPN (dilution, 1:100; R&K Systems, Inc.), anti-P-Stat3 (dilution, 1:200; Acris Antibodies, GmbH), and anti-human CD68 (dilution, 1:100; Dako). For negative controls, mouse or rabbit immune sera were used instead of primary antibodies.

Staining was revealed with a polymeric system (Novolink, Milan Polymer Detection System; Novocastra Ltd.) and visualized by using AEC High Sensitivity Substrate Chromogen Ready-to-
use (Dako Cytomation Liquid AEC Substrate Chromogen System; Dako). Slides were counterstained with hematoxylin and evaluated under a Leica DM2000 optical microscope.

**Double-marker immunofluorescence and confocal microscopy**

For double immunofluorescence, two sequential rounds of single-marker immunofluorescence were performed using CD68/OPN and CD68/arginase-1 markers. The sections were incubated with the first primary antibody (OPN or arginase-1) overnight at 4°C in a humidified chamber, then washed in PBS, and incubated for 1 hour with an Alexa Fluor 488-conjugated anti-rabbit antibody (dilution, 1:100) for arginase-1 and with an Alexa Fluor 488-conjugated anti-goat secondary antibody (dilution, 1:100) for OPN. Then, the slides were washed in PBS and incubated with CD68 for 1 hour, which was revealed using an Alexa Fluor 568-conjugated anti-mouse Ab (dilution 1:200). The sections were counterstained with DAPI (DNA stain) for 1 minute and mounted using coverslip with a drop of mounting medium and the Myeloid-Derived Suppressor Cell Isolation Kit (for separation of the two subsets; Miltenyi Biotec) following the manufacturer’s instructions.

For an *in vitro* suppression assay, 4 × 10^5 naïve BALB/c splenocytes were labeled with carboxyfluorescein succinimidyl ester (CFSE; Sigma-Aldrich) and cocultured with the different MDSC population at different ratios in the presence of 2 µg/mL of soluble anti-CD3 and 1 µg/mL of anti-CD28 to activate lymphocytes. Each sample was seeded in triplicate. Proliferation of CD4 and CD8 T cells was assessed 2 and 3 days later, by flow cytometry evaluating CFSE dilution in the CD4^+^- and CD8^-gated populations. Results are shown as the percentage of proliferated cells.

**RNA extraction and qPCR**

For qPCR analysis, MDSC subsets and other leukocyte populations were purified from the lungs of tumor-bearing mice, pooling at least 5 mice per group; lungs were minced and digested for 45 minutes at 37°C in collagenase/hyaluronidase solution, washed with complete medium, and stained with the specific Abs before cell sorting with a FACS Aria instrument (BD Biosciences). Purity of the different population was >99%.

RNA was purified from TRizol (Invitrogen)-dispersed cells by phenol/chloroform extraction followed by loading onto an RNeasy MINI or MICRO kit (Qiagen). On-column DNase treatment was routinely performed. RNA purity and yield was assessed using NanoDrop. RNA was reverse transcribed using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems). qPCR reaction was prepared using TaqMan Fast Universal PCR Master Mix and run on a 7900 HT Fast Real-time PCR System (Applied Biosystems). The following TaqMan probes were used: *Gapdh* (Mm99999915_g1), *Spp1* (Mm00436767_m1), *Arg-1* (Mm00475988_m1), *Nos2* (Mm00440502_m1), *Il6* (Mm00446190_m1), *Stat3* (Mm01219775_m1), *Vegf* (Mm01281449_m1), and (Mm01178820_m1).

**Statistical analysis**

For evaluation of lung metastases, data were represented singularly, and median was shown in the graph; statistical significance was evaluated with the Mann–Whitney test using Prism 5 software. For all the other experiments, data were represented as mean ± SD, and an unpaired two-tailed Student *t* test was used for statistical analysis.

**Results**

**RNA interference of OPN expression affects *in vitro* and *in vivo* metastatic phenotype of mammary adenocarcinoma**

RNA interference was used to generate stable OPN-silenced 4T1 mammary cancer cells using three different sequences, 215, 527, and 602 (see Materials and Methods and Supplementary Data). Efficiency of gene silencing was evaluated by Western blot analysis on cell lysates and by ELISA on cell supernatants (Supplementary Fig. S1A and S1B); as a control we used cells transduced with nontarget sequence (4T1 NT). Initial *in vitro* and *in vivo* experiments were conducted with all the three silenced clones, and with clone 527 thereafter (4T1silOPN527).
Migratory ability of silenced clones assessed across Transwell membranes was significantly inhibited in comparison with that of parental and NT control (Supplementary Fig. S1C). Consistently, OPN neutralization by an anti-OPN antibody markedly diminished the migration of 4T1 wild-type (WT) and control cells (Supplementary Fig. S1D). Anchorage-independent growth, evaluated in soft agar, showed no difference in the number of colonies (Supplementary Fig. S1E, top), despite a reduction in size of 4T1silOPN527 colonies (bottom). No difference was detected in proliferation rate in vitro (not shown).

OPN-silenced 4T1 cells and their WT and NT control counterparts injected into the mammary fat pad formed primary tumors with similar size and onset (Fig. 1A). Immunohistochemical analysis of OPN expression on tumor nodules
confirmed efficient OPN downmodulation in the case of silencing (Fig. 1B). On the other hand, the evaluation of spontaneous metastases showed that OPN-silenced 4T1 clones have significantly reduced metastatic capacity (Fig. 1C and D and Supplementary Fig. S1F).

Injection of tumor cells directly into the bloodstream bypasses the initial steps of the metastatic process such as tumor detachment and cell extravasation. Intravenous injection of 4T1silOPN527 cells induced significantly less metastases to the lungs than OPN-proficient controls, indicating that tumor-derived OPN is required for a late step of metastasis, from circulation to the seeding into the target organ (Fig. 1E). Consistently, other OPN-silenced clones were also less metastatic upon i.v. injection (Supplementary Fig. S1G).

Host-derived OPN contributes to the metastatic spread of breast cancer polarizing myeloid cells toward immunosuppression

Once demonstrated that tumor-derived OPN works mainly autocrinally, conferring survival advantage in anoxics conditions, we tested whether or not host-produced OPN contributed to metastasis. This possibility stems from the reported activity of OPN in skewing macrophages to a M1 phenotype through downmodulation of IL10 and upregulation of IL12 production (22), and could, theoretically, negatively affect tumor growth and metastasis. Therefore, we injected 4T1 cells in WT and Spp1−/− mice and, to exclude any masking effect exerted by the high endogenous expression of OPN by 4T1 parental cells, 4T1silOPN527 cells were also included.

4T1 cells formed significantly lower numbers of metastases in Spp1−/− mice than WT counterparts (Fig. 2A), despite similar primary tumor growth (not shown), demonstrating that host-derived OPN also contributes to metastasis. The lower metastatic ability of 4T1 cells in Spp1−/− mice was evidenced in the case of i.v. injection, indicating that host-derived OPN is required at later stages of metastasis directly at the seeding organ (Fig. 2B). The paucity of 4T1silOPN527 metastasis in WT mice did not allow us to detect further decrease in metastasis in Spp1−/− animals (Fig. 2A).

Whether accessory cells involved in breast cancer metastasis, such as macrophages (23), MDSC (24–26), and T cells (27, 28), might use OPN to favor the metastatic process remains unknown.

First, we analyzed the MDSC population, identified as CD11b+/Gr-1+ cells in the mouse, because of their reported role in 4T1 breast cancer metastasis (25, 29, 30) and of their huge expansion in the lungs of tumor-bearing mice, where they represent 70% to 80% of the infiltrating leukocytes. Overall, the number of CD11b+/Gr-1− cells was not different in lungs of Spp1−/− and WT tumor-bearing mice, whereas splitting the myeloid population into the two subsets of Gr-1high (granulocytic) and Gr-1int/low (monocytic) cells highlighted a significant change in their ratio: expanded Gr-1high subset in Spp1−/− mice at the expense of the Gr-1int/low, more suppressive, one (Fig. 2C). Such difference was tumor induced because lungs and spleens of tumor-free mice showed a similar ratio between the two subsets regardless of the Spp1 genotype (Supplementary Fig. S2A).

As OPN may have a role in protection from apoptosis, we determined whether lung MDSC from Spp1−/− tumor bearers had a different apoptotic rate than their WT counterparts. AnnexinV/PI flow cytometry did not show strain difference for either subset (data not shown).

Notably, the Gr-1int/low subset expressed Spp1 at a much higher level than the Gr-1high population, as tested by qPCR and confirmed by double immunofluorescence, showing OPN expression mainly in CD68+ cells with monocytic appearance (Fig. 2D). This result raised the question of whether OPN plays a role in MDSC immunosuppression.

An in vitro suppressive assay, performed using the purified Gr-1high and Gr-1int/low subsets, showed that Gr-1int/low cells from WT mice were significantly more suppressive than their Spp1−/− counterparts against CD3/CD28-activated CD8 and CD4 T cells (Fig. 3A and Supplementary Fig. S2B). As expected, the suppressive ability of Gr-1int/low cells was higher than that of the Gr-1high subset.

To better characterize the Gr-1high and Gr-1int/low subsets from metastatic lungs of Spp1−/− and WT mice, qPCR was performed on genes relevant for MDSC function. Arginase-1 (Arg-1), Tgfβ1, Il6, and Stat3 were higher in the Gr-1int/low than in the Gr-1high subsets; vice versa, Nos2 was higher in the Gr-1high than in the Gr-1int/low cells (Fig. 3B). Strikingly, Arg-1 expression in the Gr-1int/low subset was repressed in Spp1−/− mice, supporting the idea of a less suppressive phenotype we observed in the absence of OPN (Fig. 3A). A similar trend, although not statistically significant, was observed for Stat3, Il6, Tgfβ1, and Vegf, with their expression reduced in Spp1−/− mice. In metastatic lungs, double immunofluorescence analysis confirmed the colocalization of OPN and arginase-1 (Fig. 3C), whereas IHC for phospho (P)-STAT3 stained only cells with a monocytic appearance, which was represented more in WT than Spp1−/− mice (Supplementary Fig. S3).

To test whether OPN from MDSC was truly relevant for the metastatic spread of 4T1 cells, coinjection experiments were performed. WT, but not Spp1−/−, MDSC isolated from the spleen of tumor-bearing mice increased lung metastases when coinjected with 4T1 cells (Fig. 3D), and even more significantly when coinjected into Spp1−/− hosts. No effect was observed when bone marrow–derived macrophages

Published OnlineFirst July 17, 2014; DOI: 10.1158/0008-5472.CAN-13-3334
from either Spp1−/− or WT mice were partners of the coinjection (not shown).

These results indicate that myeloid cell–produced OPN favors the metastatic spread of 4T1 carcinoma.

Host-derived OPN molds immunosuppression at the metastatic site

To test whether host OPN deficiency affected other leukocyte populations infiltrating the lungs of tumor-bearing mice, we performed multiparametric FACS analysis comparing Spp1−/− and WT mice. No substantial difference in total CD11b+ cells (confirming the previous data) and overall CD4+ T cells and CD8+ T cells was detected. Nevertheless, intracellular staining for the FoxP3 transcription factor, identifying regulatory T cells (Treg), showed a reduced frequency of CD4+FoxP3+ cells in Spp1−/− mice (Fig. 4A), a result confirmed by IHC analysis on lung sections (Fig. 4B). A reduced Treg number was associated with increased frequency of CD4+–activated T cells (detected as CD44+CD69+ and CD62LlowCD69+ cells) in Spp1−/− mice (Supplementary Fig. S4A and S4B). On the same leukocyte populations, sorted from the lungs of tumor-bearing mice, we evaluated by qPCR the level of Spp1 expression to assess whether other cells, besides MDSC, express it. We confirmed a high Spp1 level in the Gr-1int/low MDSC subset, whereas other leukocytes express it at a much lower level (Supplementary Fig. S4C).

Altogether, these data point to a role of host-derived OPN, mostly from monocytic MDSC, in tuning the immunosuppressive microenvironment of the metastatic lung niche.

Tumor-produced OPN contributes to local immunosuppression

We tested whether tumor-produced OPN contributed to molding the local immunosuppression in lung metastases. No significant differences were observed in leukocytes distribution and ratio in 4T1silOPN227 versus 4T1 metastatic lungs;
MDSC number and ratio, as well as Treg number, were similar in lungs of mice bearing either parental or OPN-silenced 4T1 tumors (not shown). However, the analysis of in vitro suppressive activity of MDSC isolated from the lungs of mice bearing 4T1 cells or their OPN-silenced counterpart showed less suppression of T-cell proliferation in case Gr1int/low cells were from mice bearing 4T1silOPN527 tumors (Fig. 5A). Accordingly, this subset expressed lower level of Arg1 and Nos2 than its...
counterpart isolated from 4T1 WT tumor-bearing mice (Fig. 5B). No different expression for Il6, Vegf, Tgfb1, and Stat3 was detected (not shown).

Considering that 4T1silOPN cells produce less metastases than the 4T1 counterpart, their contribution in terms of immunomodulatory factors should be reduced, explaining the lower immunosuppressive capacity of myeloid cells in infiltrating these metastatic lungs. Either alternatively or concomitantly, the downmodulation of OPN expression in tumor cells may alter their secretion of immunosuppressive factors. This was indeed the case, at least for Vegf and Il6 that were less expressed in OPN-silenced tumor cells (Fig. 5C).

Different form and cellular localization of OPN may account for the various activities of tumor- and host-derived OPN

Although tumor-derived OPN contributes to shaping MDSC immunosuppressive activity, 4T1 cells, fully competent for OPN production, are not able to compensate for the absence of OPN in the host, and when injected into Spp1−/− mice, these cells show severely impaired metastatic ability.

To explain such observation, we considered the recently described intracellular form of OPN (iOPN), which has been found enriched in cells of the monocytic lineage (31), and we hypothesized that tumor cells produce OPN mainly in the secreted form (sOPN), whereas myeloid cells in the intracellular form.

We evaluated the amount of sOPN in the supernatant from tumor and myeloid cells in relation to their OPN expression by qPCR. One million 4T1 tumor cells secreted roughly 1 μg/mL/24 hours of OPN, which was almost undetectable in the supernatant from myeloid cells (Fig. 6A). Although gene expression data by qPCR confirmed the trend of a much higher level in tumor cells than in myeloid cells, the ratio is not so striking as in the ELISA assay (300× vs. 10,000× in qPCR and ELISA, respectively; Fig. 6B). In addition, considering that qPCR data account for both sOPN and iOPN, it is likely that most OPN from tumor cells is secreted, whereas that from myeloid cells is retained in the cell. This interpretation was confirmed by confocal analysis showing that in tumor cells OPN was mainly cytoplasmic and colocalized with concanavalin A (staining ER), whereas in monocytic myeloid cells, OPN remained confined to specific spots under the cellular membrane, as reported in ref. 31, and not localized in the ER (Fig. 6C).

The requirement for host-produced OPN in lung metastasis is not restricted to the 4T1 tumor model

To assess whether host-derived OPN favors metastatic dissemination of mammary carcinomas other than the 4T1 model, the BJMC3879 adenocarcinoma (18, 19), another spontaneously metastasizing BALB/c breast tumor, was tested. Along with tumor progression, BJMC3879 expanded CD11b+/Gr-1+ cells in PBL, spleen, and lungs (data not shown) and, phenocopying 4T1 cells, produced similar primary tumors but less lung metastases in Spp1−/− than WT mice (Fig. 7A–C). In addition, similar to the 4T1 model, the CD11b+/Gr-1+ cell population showed an increase in the Gr-1high fraction in the absence of OPN (Fig. 7D). These data indicate that the effect of...
Figure 5. Role of tumor-derived OPN in the modulation of MDSC activity. A, in vitro suppressive activity of the Gr-1^{high} and Gr-1^{int/low} subsets isolated from the lungs of mice bearing 4T1 WT and 4T1silOPN tumors. Naïve T cells were stained with CFSE and then seeded with scalar doses of Gr-1^{high} or Gr-1^{int/low} cells in the presence of α-CD3 and α-CD8 Abs for stimulation. Suppressive activity was evaluated 3 days later. Each sample is in triplicate. Graphs show mean and SD of the triplicates. B, real-time PCR for Arg1 and Nos2 in the Gr-1^{high} and Gr-1^{int/low} subsets isolated from the lungs of mice bearing 4T1 WT and 4T1silOPN tumors. Each sample is a pool of 7 mice; qPCR was performed twice on the same samples. Gr-1^{high} cells from 4T1 WT-bearing mice were used as a reference (ΔΔCt). C, real-time PCR for Vegf and IL-6 in 4T1 and 4T1silOPN cells in comparison to Gr-1^{high} cells from 4T1 WT-bearing mice was used as a reference. The experiment was performed in triplicate and repeated twice (*, P < 0.05; **, P < 0.01).
host-produced OPN in breast cancer lung metastasis is not restricted to the 4T1 tumor model.

**OPN stains myeloid cells in lung metastasis from breast cancer patients**

To assess whether our finding in the mouse models has any clinical correlation, we evaluated the expression of OPN in lung metastases from 5 patients with breast cancer undergoing metastasectomy (see Supplementary Table S1 for clinical parameters). In the cases evaluated, OPN expression was detected in cells with monocytic morphology in infiltrating metastatic cancer foci (Fig. 7E). Double immunofluorescence analysis using Abs for human OPN and the monocytic/macrophagic marker CD68 confirmed the myeloid/monocytic nature of OPN-expressing cells infiltrating breast carcinoma lung metastases (Fig. 7F).

**Discussion**

Tumor development and progression require a suitable microenvironment in which tumor cells conscript and corrupt normal resident cells, such as fibroblasts and endothelial cells, while recruiting accessory cells from the bone marrow toward their needs (32). Besides cellular elements, tumor stroma comprises the ECM, a complex network of macromolecules with different physical, biochemical, and biomechanical properties, also relevant for tumor progression and metastasis (33). Among matricellular proteins, OPN has been extensively studied as a tumor cell product conferring migratory, adhesive, and growth capacity. Whether OPN produced by stromal cells contributes to tumor progression and metastasis has not been defined. Here, we have dissected the role of OPN in breast cancer primary tumor growth and metastasis when its production was either tumor or host derived. Whereas our data substantially agree with the available literature in finding tumor-derived OPN prometastatic, the effect on primary tumor was negligible in our models, while rather relevant in other transplantable tumors (34–37). The effects of OPN inhibition in tumor cells have been investigated mainly in vitro testing cell adhesion, migration, invasion through Matrigel (34, 35, 37) or cell proliferation (38). Silencing OPN in 4T1 tumor cells, we obtained concordant inhibition of cell migration and invasion but no effect in cell proliferation and adhesion to different substrates (data not shown). Such in vitro effects, however, found little correlation with the in vivo metastatic activity we observed, in which tumor-produced OPN renders
the cells intrinsically more resistant to apoptosis while in the blood stream, rather than favoring detachment from the primary site or intravasation. Accordingly, we found a similar antimes...
transition (EMT) phenotype between OPN-silenced or WT primary tumors (not shown). Nevertheless, data showing smaller soft-agar colonies (Fig. 1D), and smaller metastatic foci in the lungs of mice injected with OPN-silenced tumor cells, suggest that OPN might also contribute to lung parenchyma colonization.

Here, we provide novel findings showing that host-derived OPN, in particular from myeloid cells, molds the immunosuppressive microenvironment at the metastatic niche. The metastatic potential of mammary tumors was greatly reduced when the recipient mice were OPN deficient, despite the fact that tumor was fully competent for OPN production, and the primary tumor grew unmodified. The analysis of the immune microenvironment at the metastatic site (i.e., lungs) showed that OPN favors the presence of immunosuppressive leukocytes, and that such leukocytes were less suppressive in Spp1+/− mice. Myeloid cells endowed with suppressive activity, generally termed MDSC, comprise two main subsets in the mouse, which can be distinguished by the different expression of the Gr-1 marker: highly expressed on the most abundant, mouse, which can be distinguished by the different expression of Spp1/C0. The analysis of the two MDSC subsets in favor of the Gr1high population and the reduced suppressive activity of the remaining Gr1int/low subset create a lung microenvironment less permissive to metastasis. The reduced suppressive of spp1+/− Gr1int/low cells correlated with a lower expression of Arg-1, IL6, and Stat3, all marks of immunosuppression highly expressed in OPN-proficient MDSC (Fig. 3B). In vivo, coinjection of tumor cells with MDSC from either Spp1+/− or WT mice confirmed that only those from WT mice promoted metastasis of 4T1 cells, regardless of the Spp1 genotype of recipient mice (Fig. 3D). Whether MDSC are produced or recruited differently from the bone marrow or whether they can transdifferentiate locally in relation to Spp1 genotype is currently unknown.

The absence of host OPN seems to affect other aspects of local immune response in the lung metastatic niche, that is, it associates with a decrease in the number of Treg and with enhanced activation of CD4 T cells. Although OPN influences MDSC-suppressive activity, it does not modify Treg-mediated immunosuppression, at least in vitro, according to our unpublished data. Whether the effect on Treg number depends directly on the different MDSC population in Spp1+/− versus WT mice deserves further investigation.

The MDSC compartment was affected not only by host-derived but also by tumor-produced OPN (Fig. 5), likely because OPN-silenced tumors form less metastases and contribute less in producing immunosuppressive factors, such as VEGF and IL6.

Despite such contribution from tumor-derived OPN, 4T1 cells, fully competent for OPN production, are not able to compensate their absence in the host, and when injected into Spp1+/− mice show severely impaired metastatic ability. To explain this datum, we investigated OPN localization in tumor and myeloid cells. Indeed, other than the soluble OPN, an intracellular form (iOPN) has been recently identified in leukocytes, particularly in cells of the monocytic lineage (31). Combining dosage of secreted OPN by ELISA with qPCR expression analysis and confocal microscopy (Fig. 6), we demonstrate that tumor cells produce OPN in high amount in the secreted form, localized within the Golgi apparatus and ER. Differently, in myeloid cells, OPN is mainly condensed in specific spots localized in perimembrane areas, phenocopying the described iOPN localization (33).

The newly described role of host-derived OPN in metastasis was corroborated using a different spontaneously metastatic breast carcinoma model, the BJM3879 cell line (41), that formed less spontaneous lung metastases when injected into Spp1+/− mice (Fig. 7A–D). Very few reports analyzed the role of host-produced OPN in tumor progression (14, 15, 35). Two reports (14, 15) studied carcinogen-induced papilloma and cutaneous squamous cell carcinoma (SCC), induced directly into Spp1+/− mice, therefore in complete absence of OPN in both host and tumors. The study from Chakraborty and colleagues (35) was the only one on breast cancer and showed a protumorigenic activity of host-derived OPN through the induction of oncogenic molecules, such as MMPs and uPA, and of angiogenesis, without considering the effect on metastasis.

Our demonstration that myeloid-derived OPN contributes to the immunosuppressive environment required for metastasis opens the question of whether other matricellular proteins may regulate tumor-associated immune responses and adds a whole new pathway to those involved in MDSC fitness. Moreover, this study further enforces the concept that matricellular proteins may produce different effects at discrete phases of tumor progression, according to their tumor-intrinsic or microenvironment-associated expression (42).

Notably, our data find clinical correlation in the presence of myeloid cells producing OPN in lung metastases of human ductal mammary carcinomas. In these samples, OPN expression was detected in scattered reactive cells with monocytoid morphology that were mostly localized within the stroma at the interface between the metastatic foci and the surrounding lung parenchyma, suggesting a role in the local events underlying constitution of the metastatic niche. The in-depth characterization of OPN-expressing cancer-associated myeloid populations and their potential biologic/prognostic relevance in cancer patient cohorts will represent an appealing issue of investigation.

In conclusion, our work is the first to show a role for both tumor- and host-derived OPN toward metastatic dissemination.
through the modulation of local immunosuppression in the lung metastatic niche.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Authors’ Contributions
Conception and design: M.P. Colombo, C. Chiodoni
Development of methodology: S. Sandri, C. Chiodoni
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): S. Sangaletti, C. Tripodo, S. Sandri, L. Torselli, C. Vitali, C. Ratti, L. Botti, A. Buronchi, A. Tomirotti
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): S. Sangaletti, C. Tripodo, S. Sandri, C. Vitali, C. Chiodoni
Writing, review, and/or revision of the manuscript: S. Sangaletti, C. Chiodoni
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): R. Porcasi
Study supervision: M.P. Colombo, C. Chiodoni

References

Acknowledgments
The authors thank Dr. Shibata (Osaka, Japan) for providing the BJMC3879 cell line and Ivano Arioli and Barbara Cappetti for technical assistance. The authors also thank the Conventional and Confocal Microscopy Facility for confocal acquisition, and the Cell Sorting Facility for MDSC subsets cell sorting of the institute.

Grant Support
This work was supported by the Associazione Italiana per la Ricerca sul Cancro (AIRC: Investigator Grants 10137 to M.P. Colombo and Program Innovative Tools for Cancer Risk Assessment and Diagnosis, 5 per mille n° 12162 to M.P. Colombo and C. Tripodo; MAFG n° 12830 to S. Sangaletti) and the Italian Ministry of Health.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received November 25, 2013; revised May 29, 2014; accepted June 13, 2014; published OnlineFirst July 17, 2014.


# Osteopontin Shapes Immunosuppression in the Metastatic Niche

Sabina Sangaletti, Claudio Tripodo, Sara Sandri, et al.


<table>
<thead>
<tr>
<th>Updated version</th>
<th>Access the most recent version of this article at: doi:10.1158/0008-5472.CAN-13-3334</th>
</tr>
</thead>
<tbody>
<tr>
<td>Supplementary Material</td>
<td>Access the most recent supplemental material at: <a href="http://cancerres.aacrjournals.org/content/suppl/2014/07/21/0008-5472.CAN-13-3334.DC1">http://cancerres.aacrjournals.org/content/suppl/2014/07/21/0008-5472.CAN-13-3334.DC1</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Cited articles</th>
<th>This article cites 42 articles, 19 of which you can access for free at: <a href="http://cancerres.aacrjournals.org/content/74/17/4706.full.html#ref-list-1">http://cancerres.aacrjournals.org/content/74/17/4706.full.html#ref-list-1</a></th>
</tr>
</thead>
<tbody>
<tr>
<td>Citing articles</td>
<td>This article has been cited by 2 HighWire-hosted articles. Access the articles at: /content/74/17/4706.full.html#related-urls</td>
</tr>
</tbody>
</table>

**E-mail alerts** Sign up to receive free email-alerts related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

**Permissions** To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.